Roger Pomerantz, Director at Rubius Therapeutics, Inc. (RUBY), bought 100 shares at $23.00 ($2K) on 2018-07-20, disclosed to the SEC on 2018-07-23.
Open-market purchase of $2k RUBY by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| MCRB | SELL | 2018-07-12 | $9K | — | Filing → |
| MCRB | SELL | 2018-07-10 | $590K | — | Filing → |
| MCRB | SELL | 2018-06-29 | $238K | — | Filing → |